Cargando…
Review of guidelines on the treatment of metastatic renal cell carcinoma
Guidelines on the management of metastatic renal cell carcinoma (rcc) have emerged over the last couple of years because of the introduction of effective new targeted therapies. However, current guidelines are not always contemporary because of older data whose relevance is unclear in the context of...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687806/ https://www.ncbi.nlm.nih.gov/pubmed/19478902 |
_version_ | 1782167597045776384 |
---|---|
author | Soulières, D. |
author_facet | Soulières, D. |
author_sort | Soulières, D. |
collection | PubMed |
description | Guidelines on the management of metastatic renal cell carcinoma (rcc) have emerged over the last couple of years because of the introduction of effective new targeted therapies. However, current guidelines are not always contemporary because of older data whose relevance is unclear in the context of the new therapies. Moreover, many of the relevant trials were interrupted prematurely because of significant advantages in progression-free survival. These circumstances sometimes make interpretation of the data and characterization of subgroups rather difficult. The current paper reviews the major guidelines available on the management of metastatic rcc and tries to put them into context. |
format | Text |
id | pubmed-2687806 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Multimed Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-26878062009-05-28 Review of guidelines on the treatment of metastatic renal cell carcinoma Soulières, D. Curr Oncol Urologic Oncology Guidelines on the management of metastatic renal cell carcinoma (rcc) have emerged over the last couple of years because of the introduction of effective new targeted therapies. However, current guidelines are not always contemporary because of older data whose relevance is unclear in the context of the new therapies. Moreover, many of the relevant trials were interrupted prematurely because of significant advantages in progression-free survival. These circumstances sometimes make interpretation of the data and characterization of subgroups rather difficult. The current paper reviews the major guidelines available on the management of metastatic rcc and tries to put them into context. Multimed Inc. 2009-05 /pmc/articles/PMC2687806/ /pubmed/19478902 Text en 2009 Multimed Inc. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Urologic Oncology Soulières, D. Review of guidelines on the treatment of metastatic renal cell carcinoma |
title | Review of guidelines on the treatment of metastatic renal cell carcinoma |
title_full | Review of guidelines on the treatment of metastatic renal cell carcinoma |
title_fullStr | Review of guidelines on the treatment of metastatic renal cell carcinoma |
title_full_unstemmed | Review of guidelines on the treatment of metastatic renal cell carcinoma |
title_short | Review of guidelines on the treatment of metastatic renal cell carcinoma |
title_sort | review of guidelines on the treatment of metastatic renal cell carcinoma |
topic | Urologic Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687806/ https://www.ncbi.nlm.nih.gov/pubmed/19478902 |
work_keys_str_mv | AT soulieresd reviewofguidelinesonthetreatmentofmetastaticrenalcellcarcinoma |